Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21711336 | 0.98 | NPC1 (0.44) | NPC1GAANNMTTDO2EGFR | |
| SCHEMBL12696794 | 0.83 | NPC1 (0.45) | NPC1GAANNMTTDO2EGFR | |
| SCHEMBL706595 | 0.80 | NNMT (0.44) | NNMTEGFRSIRT6LOXLOXL2 | |
| SCHEMBL29713548 | 0.80 | NNMT (0.44) | NNMTEGFRSIRT6LOXLOXL2 | |
| SCHEMBL31124303 | 0.80 | NNMT (0.40) | NNMTTDO2SIRT6LOXLOXL2 | |
| SCHEMBL676690 | 0.80 | NNMT (0.40) | NNMTTDO2SIRT6LOXLOXL2 | |
| SCHEMBL247318 | 0.77 | NNMT (0.37) | NPC1GAANNMTTDO2EGFR | |
| SCHEMBL25347088 | 0.77 | GAA (0.42) | NPC1GAANNMTTDO2KDM4E | |
| SCHEMBL15939077 | 0.77 | NNMT (0.50) | GAANNMTEGFRSIRT6LOX | |
| SCHEMBL15941597 | 0.77 | ALDH1A1 (0.47) | NPC1GAANNMTEGFRSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| EP-3908579-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-3749672-B1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2022-07-27 | — | — | EP | disclosed |
| US-20220089568-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3908579-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-113574054-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2004069249-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004056812-A1 | 4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | NPC1 406/4885GAA 4142/4885NNMT 3083/4885 |
| US-20220089568-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | NPC1 849/4885GAA 292/4885NNMT 789/4885 |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | NPC1 688/4885GAA 2227/4885NNMT 2552/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | NPC1 3744/4885GAA 2716/4885NNMT 1716/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | NPC1 3082/4885GAA 3334/4885NNMT 1107/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | NPC1 3082/4885GAA 3334/4885NNMT 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.